Literature DB >> 32079289

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years.

Anas Najjar1, Abderrahman Najjar2, Rafik Karaman1.   

Abstract

BACKGROUND: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached the drugs market throughout history and the recent years have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs for an efficient treatment of various ailment.
METHODS: A Scan conducted to find recent approved prodrugs and prodrugs in development.
RESULTS: Selected prodrugs were reported and categorized in accordance to their target systems.
CONCLUSIONS: the prodrug approach has shown many successes and still remains a viable and effective approach to deliver new active agents. This conclusion is supported by the recent approved prodrugs and the scan of clinical trials conducted between 2013-2018.

Entities:  

Keywords:  ACT-281959; ANAVEX 2-73; baloxavir marboxil; clinical trial; evofosfamide; fostemsavir; ixazomib; pretomanid; prodrug; selexipag

Year:  2020        PMID: 32079289     DOI: 10.3390/molecules25040884

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  6 in total

Review 1.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

2.  Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry.

Authors:  Rambabu N Reddi; Efrat Resnick; Adi Rogel; Boddu Venkateswara Rao; Ronen Gabizon; Kim Goldenberg; Neta Gurwicz; Daniel Zaidman; Alexander Plotnikov; Haim Barr; Ziv Shulman; Nir London
Journal:  J Am Chem Soc       Date:  2021-03-24       Impact factor: 15.419

Review 3.  Molecular imprinting of glycoproteins: From preparation to cancer theranostics.

Authors:  Muhammad Mujahid Ali; Shoujun Zhu; Farrukh Raza Amin; Dilshad Hussain; Zhenxia Du; Lianghai Hu
Journal:  Theranostics       Date:  2022-02-28       Impact factor: 11.556

Review 4.  Stimulus-responsive self-assembled prodrugs in cancer therapy.

Authors:  Xiao Dong; Rajeev K Brahma; Chao Fang; Shao Q Yao
Journal:  Chem Sci       Date:  2022-03-18       Impact factor: 9.825

5.  Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.

Authors:  Jinyue Ding; Rajesh Gumpena; Marc-Olivier Boily; Alexandre Caron; Oliver Chong; Jennifer H Cox; Valerie Dumais; Samuel Gaudreault; Aaron H Graff; Andrew King; John Knight; Renata Oballa; Jayakumar Surendradoss; Tim Tang; Joyce Wu; W Todd Lowther; David A Powell
Journal:  ACS Med Chem Lett       Date:  2021-05-20       Impact factor: 4.632

6.  Enhancement strategies for transdermal drug delivery systems: current trends and applications.

Authors:  Delly Ramadon; Maeliosa T C McCrudden; Aaron J Courtenay; Ryan F Donnelly
Journal:  Drug Deliv Transl Res       Date:  2021-01-20       Impact factor: 4.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.